DNA repair machinery may contribute to the mechanism of the action in imatinib. We
examined the association between the single nucleotide polymorphism (SNP) markers …

Summary The FIP1L1-platelet-derived growth factor receptor alpha and beta-positive
patients, and those with abnormal T-cell populations are currently the only clearly defined …

Simple Summary A new option to treat cancer is based on the use of so-called multi-
targeting drugs. This strategy can replace the standard treatment based on the co …

目的分析复杂变异易位慢性粒细胞白血病(CML) 的遗传学检查特点及预后情况,
提高对疾病的认识. 方法对15 例复杂变异易位CML 病例进行回顾性分析, 包括细胞形态学 …

Regulation of gene expression downstream of the Receptor Tyrosine Kinase signaling
pathway in Drosophila relies on a transcriptional effector network featuring two conserved …

The resistance for the tyrosine kinase inhibitors in chronic myeloid leukemia (CML) occurs
mainly due to BCR/ABL1 dependent and independent mechanisms. The defective DNA …

Imatinib mesylate is now the first-choice treatment for all newly diagnosed CML patients, but
despite the impressive percentage of responding patients, some CML cases show primary …

The successful introduction of the tyrosine kinase inhibitors has revolutionized the treatment
of patients with chronic myeloid leukemia (CML). Imatinib therapy induced high rates of …

Leukemia is a many-sided molecular disorder that arises because of over expression of
oncogenes, suppression of tumor suppressor genes, and chromosomal translocations …

The oncogenic BCR/ABL tyrosine kinase induces constitutive enhanced “spontaneous” DNA
damage and unfaithful repair in Philadelphia chromosome positive leukemia cells. Here, we …